Abstracts tagged "COVID-19"

Abstract Number: 1212 • ACR Convergence 2022
Immunogenicity After Primary COVID-19 Vaccination in Patients with Immune-mediated Inflammatory Diseases: A Comparative Cohort Study
Kastriot Kastrati¹, Daniel Mrak², Peter Weber³, Lena Goethans³, Claudia Hana³, Elisabeth Simader², Thomas Hummel³, Eleonora Friedberg³, Daniel Aletaha⁴, Michael Bonelli² and Helga Radner², ¹Division of Rheumatology, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Vienna, Austria, ⁴Medical University Vienna, Wien, Austria
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) are at increased risk of severe COVID-19 disease courses. Real-world data on immunogenicity are scarce but crucial to…
Abstract Number: 1744 • ACR Convergence 2022
Immune Responses to mRNA Vaccines Against SARS-CoV-2 in Patients with Immune-mediated Inflammatory Rheumatic Diseases
Cristiana Sieiro Santos¹, Sara Calleja Antolín¹, Clara Moriano Morales², Carolina Álvarez Castro¹, Elvira Díez Álvarez¹ and Jose Maria Ruiz de Morales¹, ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital León, León, Spain
Background/Purpose: Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated extraordinary efficacy…
Abstract Number: 1929 • ACR Convergence 2022
Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
Dizon Brian¹, Christopher Redmond², Emily Gotschlich³, Sangeeta Sule⁴, Tova Ronis⁴, Kathleen Vazzana⁵, Matthew Sherman⁶, Rachael Connor⁷, Abigail Bosk⁴, Niti Dham⁴, Ashraf Harahsheh⁴, Elizabeth Wells⁴, Roberta DeBiasi⁴ and Hemalatha Srinivasalu⁴, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Institutes of Health, Rockville, MD, ³FDA, Washington, DC, ⁴Children's National Hospital, Washington, DC, ⁵Arnold Palmer Hospital for Children, Orlando, FL, ⁶Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH); Children’s National Hospital, Washington, DC, ⁷Children's National Medical Center, Washington, DC
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a clinical entity distinct from primary COVID-19 infection that resembles Kawasaki disease (KD) and toxic shock syndrome.…
Abstract Number: 2195 • ACR Convergence 2022
Pre-exposure Prophylaxis for SARS-CoV-2 with Subcutaneous Casirivimab/Imdevimab in Vaccine-refractory Patients with Immune-mediated Inflammatory Diseases
Filippo Fagni¹, Katja Schmidt², Daniela Bohr³, Larissa Valor Mendez⁴, Ioanna Minopoulou², Melek Yalcin Mutlu², Fabian Hartmann², Koray Tascilar⁴, Karin Manger⁵, Bernhard Manger², Arnd Kleyer⁴, David Simon⁴, Georg Schett⁶ and Thomas Harrer², ¹University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ²University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Rheumatology Practice Bamberg, Bamberg, Germany, ⁶Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Humoral responses to SARS-CoV-2 vaccination are reduced in patients with immune-mediated inflammatory diseases (IMID), especially when treated with B-cell depletion therapies, leading to increased…
Abstract Number: L03 • ACR Convergence 2021
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine
Kyriakos Kirou and Jeffrey Zhang-Sun, Hospital for Special Surgery, New York, NY
Background/Purpose: Optimal COVID-19 vaccine responses are necessary to protect against severe infection. Patients with systemic rheumatic diseases (SRD) are at risk for not mounting adequate…
Abstract Number: L04 • ACR Convergence 2021
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry
Jean Liew¹, milena Gianfrancesco², Carly Harrison³, zara Izadi², Stephanie Rush², Lindsay Jacobsohn², Clairissa Ja², Saskia Lawson-Tovey⁴, Kimme Hyrich⁵, Laure Gossec⁶, Anja Strangfeld⁷, Loreto Carmona⁸, Martin Schaefer⁷, ELSA MATEUS⁹, Samar Al Emadi¹⁰, Claire Cook¹¹, Fatemah Abutiban¹², Dfiza Dey¹³, Emily Kowalski¹⁴, Marco Martinez-Martinez¹⁵, Naomi Patel¹¹, Evelyn Salido¹⁶, Jeffrey Sparks¹⁷, leanna Wise¹⁸, Suleman Bhana¹⁹, Wendy Costello²⁰, Rebecca Grainger²¹, Jonathan Hausmann²², Emily Sirotich²³, Paul Sufka²⁴, Zachary Wallace²⁵, Pedro Machado²⁶, Philip Robinson²⁷ and Jinoos Yazdany², ¹Boston University School of Medicine, Boston, MA, ²University of California San Francisco, San Francisco, CA, ³Lupus Chat, New York, NY, ⁴Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France, Paris, France, ⁷German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany, ⁸Instituto de Salud Musculoesquelética, Madrid, Spain, ⁹EULAR, Lisboa, Portugal, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Massachusetts General Hospital, Boston, MA, ¹²Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, KUWAIT, Kuwait, ¹³Rheumatology Unit , Department of Medicine and Therapeutics, University of Ghana Medical School, Korle Bu Teaching Hospital, Accra, Ghana, ¹⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁵Instituto Mexicano del Seguro Social, San Luis Potosí, Mexico, ¹⁶University of the Philippines Manila, Manila, Philippines, ¹⁷Brigham and Women's Hospital, Boston, MA, ¹⁸University of Southern California, Los Angeles, CA, ¹⁹Pfizer, Montvale, NJ, ²⁰Irish Children's Arthritis Network (iCAN), Bansha, Ireland, ²¹University of Otago, Wellington, New Zealand, ²²Boston Childrens Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²³McMaster University, Hamilton, ON, Canada, ²⁴HealthPartners, Eagan, MN, ²⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²⁶Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom, ²⁷University of Queensland School of Clinical Medicine, Herston, Queensland; Department of Rheumatology, Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service, Queensland, Australia., Brisbane, Australia
Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical characteristics of…
Abstract Number: L09 • ACR Convergence 2021
A Prediction Model to Distinguish Patients with Multisystem Inflammatory Syndrome in Children
Matthew Clark¹, Danielle Rankin², Alisa Gotte¹, Alison Herndon¹, William McEachern¹, Andrew Smith³, Daniel Clark¹, Edward Hardison¹, Anna Patrick¹, Lauren Peetluk¹, Natasha Halasa¹, James Connelly¹ and Sophie Katz¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³The Heart Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common infectious and…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: L18 • ACR Convergence 2021
Humoral and Cellular Immune Responses to a Second Dose of COVID-19 Vaccine BNT162b2 in People Receiving Methotrexate or Targeted Immunosuppression: A Cohort Study
Satveer K Mahil¹, Katie Bechman², Antony Raharja¹, Clara Domingo-Vila³, David Baudry¹, Matt Brown², Andrew Cope², Tejus Dasandi¹, Hataf Khan⁴, Thomas Lechmere⁴, Michael Malim⁴, Freya Meynell¹, Emily Pollock³, Kamila Sychowska³, Jonathan Barker¹, Sam Norton⁵, James Galloway², Katie Doores⁴, Timothy Tree³ and Catherine Smith¹, ¹St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, ²Centre for Rheumatic Diseases, King's College London, London, ³Department of Immunobiology, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom, ⁴Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom, ⁵Psychology Department, Institute for Psychiatry Psychology & Neuroscience, King’s College London, London
Background/Purpose: COVID-19 vaccines have robust immunogenicity in the general population. Data on individuals with immune-mediated inflammatory diseases who are taking immunosuppressants remains limited. Our cohort…
Abstract Number: L01 • ACR Convergence 2021
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full Vaccination in Patients with Inflammatory Rheumatic Diseases
Catherine Raptis¹, Diego Andrey², Christoph Berger³, Axel Finckh², Pierre Lescuyer², Adrian Ciurea⁴, Tanja Maletic¹, Christos Polysopoulos¹, Myriam Riek¹, Almut Scherer¹, Kim Lauper², Burkhard Moeller⁵, Judith Safford⁶, Sandra Schweizer⁷, Isabell von Loga¹, Nicolas Vuilleumier⁸ and Andrea Rubbert-Roth⁹, ¹SCQM Foundation, Zurich, Switzerland, ²Geneva University Hospital, Geneva, Switzerland, ³University Hospital Basel, Basel, Switzerland, ⁴University Hospital Zurich, Zrich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶RheumaCura Foundation, Zurich, Switzerland, ⁷Swiss League Against Rheumatism, Zurich, Switzerland, ⁸University Hospital of Geneva, Geneva, Switzerland, ⁹Kantonspital St Gallen, St.Gallen, Switzerland
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19 vaccines but long-term data…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: 0086 • ACR Convergence 2021
SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review
Richard Conway¹, Alyssa Grimshaw², Maximilian Konig³, Michael Putman⁴, Ali Duarte-Garcia⁵, Candice Low⁶, Shangyi Jin⁷, Diego Cabrera⁸, Yu Pei Eugenia Chock⁹, Berk Degirmenci¹⁰, Eimear Duff¹¹, Bugra Egeli¹², Elizabeth Graef¹³, Akash Gupta¹⁴, Patricia Harkins¹⁵, Bimba Franziska Hoyer¹⁶, Aruni Jayatilleke¹⁷, Christopher Kasia¹⁸, Aneka Khilnani¹⁹, Adam Kilian²⁰, Alfred Kim²¹, Chung Mun Alice Lin²², Laurie Proulx²³, Sebastian Sattui²⁴, Namrata Singh²⁵, Jeffrey Sparks²⁶, Herman Tam²⁷, Leslie Yingzhijie Tseng², Manuel Ugarte-Gil²⁸, Natasha Ung²⁹, Leanna Wise³⁰, Ziyi Yang³¹, Kristen Young³², Jean Liew³³, Rebecca Grainger³⁴, Zachary Wallace³⁵ and Evelyn Hsieh², ¹St. James's University Hospital, Dublin, Ireland, ²Yale School of Medicine, New Haven, CT, ³The Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical College of Wisconsin, Brookfield, WI, ⁵Mayo Clinic, Rochester, MN, ⁶St. Vincent's University Hospital, Dublin, Ireland, ⁷Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁸Yale School of Medicine, Lima, Peru, ⁹Yale School of Medicine, Greenwich, CT, ¹⁰St. Elizabeth's Medical Center, Boston, MA, ¹¹St. James's Hospital, Dublin, Ireland, ¹²Boston Children's Hospital, Boston, MA, ¹³Emerson Hospital, Concord, MA, ¹⁴Department of Medicine, Yale University School of Medicine, New Haven, CT, ¹⁵St James hospital, Dublin, Ireland, ¹⁶Universittsklinikum Schleswig-Holstein, Kiel, Germany, ¹⁷Temple University, Philadelphia, PA, ¹⁸The Medical College of Wisconsin, Maywood, IL, ¹⁹George Washington University School of Medicine and Health Sciences, Washington, DC, ²⁰George Washington University, Melbourne, FL, ²¹Washington University School of Medicine, St. Louis, MO, ²²Newcastle University, Newcastle, United Kingdom, ²³Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ²⁴Hospital for Special Surgery, New York, NY, ²⁵University of Washington, Bellevue, WA, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²⁸Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²⁹New South Wales Health, Sydney, Australia, ³⁰LAC+USC/Keck Medicine of USC, Pasadena, CA, ³¹Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing 100730, China, Beijing, China (People's Republic), ³²University of Texas Southwestern Medical Center, Dallas, TX, ³³Boston University, Boston, MA, ³⁴University of Otago, Wellington, New Zealand, ³⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: The relative risk of COVID-19 among patients with rheumatic and musculoskeletal disease (RMD) and the comparative severity of COVID-19 infection in RMD remain uncertain.…
Abstract Number: 0104 • ACR Convergence 2021
Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population
Laura Boekel¹, Laura Kummer², Koos van Dam², Femke Hooijberg¹, Zoé van Kempen², Erik Vogelzang², Luuk Wieske², Filip Eftimov², Ronald van Vollenhoven³, Taco Kuijpers², Marieke van Ham⁴, Sander Tas⁵, Joep Killestein², Maarten Boers⁶, Mike Nurmohamed⁷, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁷Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Clinical trials on efficacy and safety of SARS-CoV-2 vaccines did not include patients with autoimmune diseases. We previously demonstrated that concerns of adverse events…
Abstract Number: 0197 • ACR Convergence 2021
Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series
Hildrun Haibel¹, Stefan Angermair², Michael Schumann², Janis Vahldiek³, Denis Poddubnyy⁴ and Thomas Schneider², ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Medicine Berlin Campus Benjamin Franklin, Berlin, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Severe and life threating COVID-19 pneumonia is often characterized by local and systemic immune-mediated hyperinflammation At the early disease stage activated monocytes are migrating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].